by Kenjiro Lolling | Apr 15, 2025 | Events, News
Join NecstGen and ProteoNic for our webinar “Improving lentiviral vector yield with 2G UNic technology”, presented by Maurice van der Heijden (Director of R&D, ProteoNic) and Diederik Lokhorst (Viral Vector Scientist, NecstGen).
Discover more about ProteoNic’s 2G UNic™ technology and how NecstGen has been applying the technology for Lentiviral (LV) production. Learn from our experts while they discuss several aspects of LV production, a major cost driver in both gene therapies and Ex vivo gene therapies, and how both companies are working together to improve it.
Register now to secure your spot and stay tuned for more updates!
Register here
by Kenjiro Lolling | Apr 8, 2025 | Events, News
TechTalk XL – Tuesday 1 July 2025
Hosted by NecstGen in collaboration with Leiden Bio Science Park
🗓 Date: Tuesday 1 July 2025
🕒 Time: 15:30 – 19:30
📍 Location: NecstGen, Mirai House | Sylviusweg 62, Leiden
NecstGen is pleased to host the next edition of TechTalk XL during the Dutch Bio Science Week 2025 this summer. We invite you to join us for a focused afternoon of content and conversation on Cell & Gene Therapies.
The TechTalk XL programme showcases speakers and brief snapshot talks that highlight innovative breakthroughs and share practical insights across the spectrum—from development to clinical translation—of advanced therapy medicinal products (ATMPs).
Programme:
15:30 – Arrival & Registration
16:00 – Speaker Session & Q&A
- “Developing curative gene therapies for area genetic diseases” by Frank Staal (Leiden University Medical Center)
- “NTrans delivery platform – Unlocking next-generation T-cell therapies” by Ester Weijers (NTrans Technologies BV)
- “Transforming the treatment landscape of Cancer & Autoimmune diseases with stem cell-derived Natural Killer cells” by Anna-Maria Georgoudaki (Glycostem Therapeutics)
17:00 – Snapshot Talks
Short, sharp insights from emerging voices in the field.
- “Enabling end-to-end modular automation for organoid-based implants for regenerative medicine” by Isaak Decoene (KU Leuven)
- “Automated, Decentralized Production for Advanced Therapies” by Julius Mathews (Fraunhofer IPT)
- “Lighting Up Contamination: Accelerating Sterility Testing with ATP Bioluminescence” – Brice Meulah (Biotactical)
- “Safe Cells Start With Safe Donors: WMDA’s Mission to Protect the People Behind the Therapies” – Eefke van Eerden (WMDA)
From 17:30 – Networking
An opportunity to exchange ideas with peers, collaborators, and potential partners.
Additional speakers and further details will be announced shortly.
Participation is free, but seats are limited
Please register in advance by clicking here
Get a glimpse of last years event here
by Kenjiro Lolling | Apr 1, 2025 | News
Last Thursday, NecstGen had the pleasure of hosting the bioMérieux Pharma Quality Control User Group meeting “Automation and Digitalisation in Your QC Micro Lab” in Leiden, in close collaboration with the bioMérieux team.
The event brought together users of bioMérieux solutions for a full day of expert presentations, engaging discussions, a guided facility tour, and a live demonstration of 3P CONNECT—bioMérieux’s digital solution designed to streamline microbiological Quality Control (QC) processes in pharmaceutical and biopharmaceutical manufacturing.
We want to thank bioMérieux for their partnership and making this meeting possible and all participants for their active involvement and valuable insights.
A special thanks to the speakers:
Dave Bates, Stephan Pohlmann, Emilie de Bruijckere, Katarina Bredberg, Marc Vanderhaeghen-Manier, Melissa Van Pel, Kees Mensch, Jasper Donkers, and David Watson.
Bringing together expertise in this way is essential to improving the reliability and efficiency of QC in Cell and Gene Therapy manufacturing.
by Kenjiro Lolling | Mar 27, 2025 | News
NecstGen is a mission-driven CDMO, operating as a non-profit organization to challenge the high costs of CGT therapies. From our cutting-edge facility located in Leiden, The Netherlands, we are able to serve clients all over the world, including US-based companies.
Over the past few weeks, we and our partners from The Digital Capability Company (DCC) have been working with a group of students from The Georgia Tech Scheller College of Business MBA program in their consulting assignment. Their objective: to provide us with insights and recommendations on how to approach and enter the US Cell Therapy market; Our role: to support the team with sector-specific insights, such competitive intelligence from a European CDMO perspective.
Last week, we had the pleasure to host the group at our facilities, and it was great to finally meet them in person! Brooke E. Leeder Roenitz, Brandon Douglass, John Parkerson, Eric Terry and Chelsea Wright, thank you very much for the visit. It was great to host you all, we hope that you enjoyed the visit as much as we did!
Kees Mensch, Jasper Donkers and Rick Stijnen, thank you for giving us the chance to participate in this project. All of the discussions have been very insightful, and we look forward to the final recommendations from the team!
by Kenjiro Lolling | Mar 13, 2025 | News
It was great to welcome Prof. Ulrike Köhl, Director of the Fraunhofer Institute for Cell Therapy and Immunology, and Paul Franz from Fraunhofer IZI to NecstGen! Over the past two days, we provided a facility tour and had inspiring discussions on potential collaboration.
Our conversations focused on ATMP development and GMP manufacturing, key areas where Fraunhofer IZI and NecstGen are committed to driving progress. From process optimisation to clinical translation, plenty of common ground exists to explore.
As non-profit organisations, both Fraunhofer IZI and NecstGen are driven by a shared mission: enabling the development of advanced therapies and supporting innovation in cell and gene therapy. It’s always inspiring to exchange ideas with like-minded partners who put science and patient impact first.
by Kenjiro Lolling | Mar 4, 2025 | News
Last week, Diederik Lokhorst and Cristina Muñoz Lopez from NecstGen visited BIA Separations Inc./Sartorius in Slovenia for hands-on training in chromatography and analytical tools. This visit provided valuable insights into monolith technology and the PATfix analytical platform, supporting process monitoring and optimisation.
“Overall, it was a very nice experience to be there. The team is very knowledgeable and has a lot of passion for what they do. We have learned many new things, and it was fascinating to learn about their technologies, not only the monoliths but also the analytical tools like the PATfix.” – Cristina
Working alongside the experienced team at BIA Separations was an excellent opportunity to exchange knowledge and refine approaches for downstream processing. Their expertise and commitment to innovation were evident throughout the training sessions, and we look forward to applying these learnings in our work at NecstGen.
Interested in learning more about how we apply advanced chromatography in our manufacturing processes? Get in touch—we’d be happy to discuss how our expertise can support your Cell & Gene Therapy development.
